St George's NHS Healthcare Trust _NIHR Project Delivery (Meeting Target Recruitment) report 2015/16_Q3

CTP ID no	Research Ethics Committee Reference	Name of Trial	Target number of patients	Target Date for recruitment	Trial Status	Target met
70149	09/H0720/135	A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis.	4	14/10/2011	Closed - Follow Up Complete	Y
70150	10/H0713/76	A Phase 3, randomised, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects. SINGLE	2	30/04/2011	Closed - Follow Up Complete	Y
70172	12/SC/0185	A Multi-Centre 3-Year Follow-Up study to Assess the Durability of Sustained Virologic Resonse in Alisporivir-Treated Chronic Hepatitis C Patients.	1	23/03/2015	Closed - Follow Up Complete	Y
70189	13/LO/1302	A Phase IIIb randomised, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonivar plus tenofovir/emtricitabine once daily in HIV-1 infected antiretroviral therapy naive women.	4	31/08/2014	Closed - Follow Up Complete	Y
70191	13/EE/0176	Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, with MRI Substudy, of Repeated Doses of Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis.	4	31/12/2014	Closed - Follow Up Complete	Y
70200	14/YH/0049	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke.	4	31/03/2015	Closed - Follow Up Complete	Y
70201	14/NW/0017	A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients.	6	30/11/2014	Closed - Follow Up Complete	Y
70204	14/WA/0117	Pilot study to assess Topical Oxygen therapy device (Natrox) with best medical care for non-healing diabetic Foot Ulcers.	5		Closed - Follow Up Complete	Y
70212	14/YH/1057	A phase III, randomised, open-label study to compare Sofosbuvir/GS-5816 fixed dose combo for 12 weeks with sofosbuvir + RBV for 24 weeks in chronic genotype 3 HCV.	9	No date agreed with Sponsor	Closed - Follow Up Complete	Y
70215	14/LO/0665	Phase III RCT to study safety & efficacy of the combo regimen of MK-5172/MK-8742 in treatment naive subjects with HCV GT1,GT4,GT5 & GT6 infection who are on opiate substitution therapy PN:MK-5172-062	4	28/11/2014	Closed - Follow Up Complete	Y
70216	14/WM/1056	A phase IIIB Randomised, open-label study of Sofosbuvir/GS-5816 fixed dose combo for 12 weeks in chronic HCV.	7		Closed - Follow Up Complete	Y
70243	13/LO/1714	Safety, PK/PD and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anaemia: A randomized, double blind, placebo controlled parallel group study with a single blind cross-over group.	2	30/09/2015	Closed - Follow Up Complete	Y
70211	14/LO/0590	A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women.	No target agreed with sponsor	No date agreed with Sponsor	Closed - Follow Up Complete	No eligible patients at StG - no patients became pregnant on related trial
70236	14/WM/1262	An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection.	5	No date agreed with Sponsor	Closed - Follow Up Complete	No eligible patients at StG - all patients were on active arm of previous closed trial
70157	06/MRE04/84	TEMSO Extension: Long-term extension study of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14mg) in patients with multiple sclerosis with relapses.	10	No date agreed with Sponsor	Closed - Follow Up Complete	N
70158	07/H0707/112	CIS Study: An international, Multi-centre, Randomised, Double-Blind, placebo controlled parallel group study to evaluate the efficacy and safety of two year treatment with Teriflunomide 7mg once daily and 14mg once daily versus the plaebo in patients with a first clinical episode suggestive of multiple sclerosis.	7	No date agreed with Sponsor	Closed - Follow Up Complete	N
70168	10/H0808/27	Zenith TX2 Low-Profile TAA Endovascular Graft Clinical Study #08-017-03	10	30/09/2010	Closed - Follow Up Complete	N
70170	12/WS/0285	A ClinIcal EvaluatioN of ST Changes in a Group of PatIents havinG Ventricular ArrHyThmias.	15	30/04/2016	Closed - Follow Up Complete	N
70171	11/LO/0278	A long term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA containing regimens for chronic hepatitis C infection (CHC).	6	30/09/2012	Closed - Follow Up Complete	N
70173	11/YH/0379	B1971009 Phase 3 study to assess Meningococcal B Vaccine.	50	No date agreed with Sponsor	Closed - Follow Up Complete	N
70180	12/YH/0398	Assessment of clinicial effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at High Risk for Vascular Outcomes - the Accelerate Study.	15	22/10/2013	Closed - Follow Up Complete	N
70187	13/NW/0612	A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting ?2 Agonist in Patients with Uncontrolled Asthma.	1	19/12/2014	Closed - Follow Up Complete	N
70195	13/LO/1793	Self-management tools to manage adherence in Parkinson's disease.	35	31/05/2014	Closed - Follow Up Complete	N
70197	13/LO/0357	Double-Blind, Randomized, Placebo-Controlled, Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke.	4	31/07/2014	Closed - Follow Up Complete	N
70199	12/EE/0371	MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY COMPARING EXTENDED DURATION BETRIXABAN WITH STANDARD OF CARE ENOXAPARIN® FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTE MEDICALLY ILL PATIENTS.	10	01/05/2015	Closed - Follow Up Complete	N
70206	14/EE/0076	A Phase IV, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Tecfidera™ (dimethyl fumarate) delayed-release capsules.	12	30/04/2015	Closed - Follow Up Complete	N
70240	15/LO/0495	A Phase 3b, Randomised, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF).	5	30/11/2017	Closed - Follow Up Complete	N
70242	15/LO/0496	A phase 3b, randomized, double-blind study to evaluate switching from a regimen consisting of efavirenz/ emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) fixed dose combination (FDC) to emtricitabine/ rilpivirine/ tenofovir alafenamide (FTC/RPV/TAF) FDC in virologically-suppressed, HIV-1 infected subjects.	7	30/11/2017	Closed - Follow Up Complete	N
70219	14/EE/1051	Optiflow PatEncy and MaturatioN Clinical Trial	35	30/06/2015	Closed - Follow Up Complete	Global Trial halted early by sponsor
70152	10/H0803/96	A randomized, controlled, open-label, parallel-group, multi-center study to compare the effect of Intrathecal Baclofen Therapy (ITB Therapy?) versus Best Medical Treatment (BMT) on severe spasticity in post-stroke patients after 6 months active treatment.	4	31/03/2011	Closed - In Follow Up	Y
70154	11/SC/0329	A Phase 3, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease.	5	15/09/2013	Closed - In Follow Up	Y
70156	11/EE/0219	Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms.	5	No date agreed with Sponsor	Closed - In Follow Up	Y
70159	12/EM/0395	A Randomised, Double Blind, Parallel Group, Multicentre Phase IIIb study to complare ticagrelor with clopidogrel treatment on the risk of cardiovascular deat, myocardial infarction and ischeamic stroke in patients with established Peripheral Artery Disease (EUCLID - Examining the Use of tiCagrLor In paD).	20	14/06/2014	Closed - In Follow Up	Y
70174	11/NW/0298	A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMPARED WITH RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY GA101 OR RITUXIMAB MAINTENANCE THERAPY IN RESPONDERS.	6	30/06/2013	Closed - In Follow Up	Y
70175	09/H0308/124	To prospectively collect global 'real world' safety and clinical performance data on Endurant Stent Graft System. This is a registry only.	10	No date agreed with Sponsor	Closed - In Follow Up	Y
70179	12/LO/1950	A randomized, open-label, Phase 3 Trial of A+AVD vs ABVD frontline therapy in patients with advanced classical Hodgkin Lymphoma.	6	30/11/2014	Closed - In Follow Up	Y
70181	09/H1102/54	An International, Multicenter, Prospective Observational Study of the Safety of Maraviroc used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients.	5	No date agreed with Sponsor	Closed - In Follow Up	Y
70185	13/SC/0279	A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects.	1	No date agreed with Sponsor	Closed - In Follow Up	Y
70203	13/SC/0183	A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures.	2	14/03/2016	Closed - In Follow Up	Y
70208	14/EE/0102	A prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of nonvalvular atrial fibrillation.	9	31/05/2015	Closed - In Follow Up	Y
70209	14/NW/0008	GO-COLITIS: Golimumab: A Phase 4, UK, Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis.	7	31/03/2015	Closed - In Follow Up	Y
70218	14/SC/0075	A Multicenter, International, Phase 3, DoubleBlind, PlaceboControlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTRCM).	4	21/01/2019	Closed - In Follow Up	Y
70222	14/LO/0882	A phase III open-label, multicentre randomised study to investigate the efficacy and safety of MPDL3280A (anti-PD_L1 antibody) compared with docetaxel in patients with non-small cell lung cancer after failure with platinum containing chemotherapy.	4	30/06/2015	Closed - In Follow Up	Y
70224	14/LO/1243	Patient reported outcomes with Fingolimod ('PROFILE')	12	01/02/2015	Closed - In Follow Up	Y
70229	14/EE/1001	A 6-month, prospective, randomized, multicenter, placebo-controlled safety study of OTO-104 given at 3-month intervals by intra tympanic injection in subjects with unilateral Meniere's disease followed by a 6-month open-label extension (OTO-104)	8	04/02/2015	Closed - In Follow Up	Y
70230	14/LO/1513	A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF or Efavirenz /Emtricitabine/Tenofovir DF) compared to Ritonavir boosted Atazanavir plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults with eGFR =70 mL/min.	3	13/12/2015	Closed - In Follow Up	Y
70233	14/EM/1249	An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)	5	31/08/2020	Closed - In Follow Up	Y
71467	13/EE/0276	A Phase 3B Randomized, Open-Label Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection.	8	No date agreed with Sponsor	Closed - In Follow Up	Y
70251	11/LO/1772	An open label long term follow up study for patients with melanoma who were previously enrolled in the phase 1 study IMM-101-001		31/01/2016	Closed - In Follow Up	This is for Follow-up for Patients recruited at a different centre
70162	09/H1107/103	A Phase 3, Multicentre, Randomised, Open-Label, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukaemia. (The Origin Trial)	5	31/05/2011	Closed - In Follow Up	N
70151	10/H0904/49	A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis.	8	No date agreed with Sponsor	Closed - In Follow Up	N
70155	10/H0724/33	CoreValve Advance International Post Market Study A Multi-centre, Interventional, Prospective, Post-Market Release Study.	100	No date agreed with Sponsor	Closed - In Follow Up	N
70163	09/H0301/5	A Phase 3, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group study of the Efficacy and Safety of Lenalidomide (Revlimid?) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukaemia following Second-line Therapy.	5	30/11/2013	Closed - In Follow Up	N
70164	12/LO/1351	A multicentre, single arm study of Trastuzumab Emtasine (TDM-1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-HER2 and chemotherapy-based treatment.	5	30/09/2013	Closed - In Follow Up	N
70165	12/SC/0139	A Phase III Prospective, Two-cohort, Non-randomized, Multi-centre, Multi-national, Open Label Study to Assess the Safety of Assisted- and Self-administered Subcutaneous Trastuzumab as Adjuvant Therapy in Patients with Operable HER2-positive Early Breast Cancer.	6	No date agreed with Sponsor	Closed - In Follow Up	N
70166	08/H0606/29	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL vs. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOUSLY UNTREATED HER2-POSITIVE METASTATIC BREAST CANCER	5	30/09/2012	Closed - In Follow Up	N
70167	08/H0311/120	Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group	30	01/06/2013	Closed - In Follow Up	N
70169	11/LO/0922	OVATION POST-MARKET STUDY Ovation Abdominal Stent Graft System	15	No date agreed with Sponsor	Closed - In Follow Up	N
70178	12/LO/1823	A Randomized Double-blind Phase 3B Study to Evaluate the the safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Fumarate in HIV 1 Infected, Antiretrovi	10	30/09/2015	Closed - In Follow Up	N

70183	13/SW/0184	The Medtronic CoreValve EvolutR Clinical Study	10	31/05/2014	Closed - In Follow Up	N
70188	12/LO/0095	Protocol AI444-046: A long-term follow-up study of subjects who participated in a clinical trial in which BMS-650032 and/or BMS-790052 was administered for the treatment of Chronic Hepatitis C	5	No date agreed with Sponsor	Closed - In Follow Up	N
70160	12/LO/0491	Surgical replacement and transcatheter aortic valve implantation	25	31/10/2018	Closed - In Follow Up	Local PI closed this site early due to limitations of the research design as not the best clinical options for patients
70186	13/LO/1424	Prospective, nonrandomised, three-centre, pre-market clinical study eveluating subjects implanted with the Valiant Mona LSA. Thoracic Stent Graft System for the treatment of descending thoracic aneurysms that are candidates for revascularization of the left subclavian artery (LSA).	3	No date agreed with Sponsor	Closed - In Follow Up	Local PI closed this site early due to clinical outcomes
70263	12/EE/0127	A randomised double blind placebo controlled single ascending dose group study to assess the safety , tolerability, PK, Efficacfy and PD of a single intravenous administration of KBSA301 in sever pneumonia caused by staphylococcus aureous.	3	31/03/2016	In set up	N/A
70161	12/LO/1076	A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa?) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma.	5	31/05/2015	Open	Y
70182	13/LO/0826	Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection	25	30/04/2014	Open	Y
70193	12/LO/2023	Freeride-study Freeway Randomised Angioplasty Study	4	No date agreed with Sponsor	Open	Y
70194	13/EE/0326	REVACEPT, AN INHIBITOR OF PLATELET ADHESION IN SYMPTOMATIC CAROTID STENOSIS: A PHASE II, MULTICENTRE; RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PLACEBO-CONTROLLED SUPERIORITY STUDY WITH PARALLEL GROUPS.	6	30/06/2015	Open	Y
70196	12/EM/0373	A Randomized Multicentre Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem cell Transplant.	5	No date agreed with Sponsor	Open	Y
70205	13/EM/0404	A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.	10	30/04/2015	Open	Y
70207	11/EM/0398	A Phase III, multicentre, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-1431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in pediatric patients with Type 2 Diabetes Mellitus.	1	31/08/2017	Open	Y
70210	14/EE/0152	A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigratan by intravenous administration of 5.0g idarucizuma (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.	1	28/04/2017	Open	Y
70221	13/NE/0327	Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson's disease patients with motor complications not well controlled on medical treatment.	4	31/03/2015	Open	Y
70227	14/EE/0062	A prospective, multi center, study to evaluate the safety and efficacy of the Laminate external support device for brachiocephalic arteriovenous fistula.	20	30/11/2014	Open	Y
70228	14/WM/1143	A Phase II, Randomized, OpenLabel, ActiveControlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days for the Treatment of Clostridium difficile Infection (CDI)	3	31/08/2015	Open	Y
70259	15/NW/0699	A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)	5	31/03/2016	Open	Y
70190	13/NW/0006	A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas	2	31/12/2014	Open	N/A
70192	13/LO/1798	A PHASE 2A AND 2B MULTICENTER, RANDOMIZED, OPEN LABEL, MULTIPLE-DOSE STUDY OF INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION OF SOTATERCEPT (ACE-011) IN SUBJECTS WITH END-STAGE KIDNEY DISEASE ON HEMODIALYSIS SWITCHED FROM ERYTHROPOIESIS STIMULATING AGENTSWITH STAGGERED DOSE GROUP ESCALATION IN PART 1 FOLLOWED BY A PARALLEL GROUP, ACTIVE CONTROLLED STUDY OF SELECTED DOSE(S) AND REGIMEN(S) IN PART 2: TO EVALUATE THE PHARMACOKINETICS, SAFETY, TOLERABILITY, EFFICACY, DOSING REGIMEN, AND PHARMACODYNAMICS OF SOTATERCEPT.	3	30/09/2014	Open	N/A
70213	14/NW/0002	A prospective, randomized, controlled study evaluating EVICEL Fibrin sealant as an adjunct to haemostasis during abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgery in paediatric patients.	4	31/08/2015	Open	N/A
70214	14/EM/0084	A prospective, randomized, controlled, study evaluating the safety and effectiveness of EVARREST sealant matrix in controlling mild or moderate hepatic parenchyma or soft tissue bleeding during open, abdominal, retroperitoneal, pelvic and thoracic (non-cardiac) surgery in Paediatric patients.	4	31/08/2015	Open	N/A
70217	13/LO/0549	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis.	4	30/09/2015	Open	N/A
70220	14/YH/0007	A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of lacosamide as adjunctive therapy in subjects with epilepsy 4 years or over and less than 17 years of age with partial onset seizures.	4	31/05/2016	Open	N/A
70223	14/LO/0566	A randomised, double-blind,parallel group, placebo-controlled multi-centre Phase 111 study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.	4	31/12/2018	Open	N/A
70225	14/WM/0013	A randomised, double-blind, placebo-controlled ,2-Part study of orally administered ALS-008176 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dosing and multiple ascending dosing in infants hospitalised with Respiratory Syncytial Virus (RSV) infection.	4	31/03/2016	Open	N/A
70226	14/NI/1075	A phase I/IIa Multicentre study in otherwise healthy infants and toddlers hospitalised for and diagnosed with respiratory syncytial virus lower respiratory tract infection, consisting of an open-label lead-in part followed by a doubleblind, placebo-controlled part, to evaluate the safety, tolerability and clinical activity of ALX-0171, administered via inhalation, in addition to standard of care.	1	01/10/2015	Open	N/A
70231	14/LO/1468	Starpharma: SPL7013-018 BV_Phase 3 study of vivagel in bacterial vaginosis.	10	31/10/2015	Open	N/A
70232	14/YH/0086	RESPOND: Repositionable Lotus Valve System – Post Market Evaluation of Real World Clinical Outcomes	15	31/12/2015	Open	N/A
70234	14/NW/1258	A multinational, randomised, double-blind, placebo-controlled phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (Orion Aramis)	4	No date agreed with Sponsor	Open	N/A
70235	15/LO/0049	Evaluation of overall therapy cost comparing first intention and second intention heated humidification for CPAP: A pilot study.	20	01/04/2016	Open	N/A
70237	15/EM/0021	A randomised, double blind, placebo controlled multicenter trial, examining the effect of Natrox™ on the rates of healing for chronic diabetic foot ulcers.	10	31/07/2015	Open	N/A
70241	14/SC/1311	A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms.	3	31/05/2016	Open	N/A
70244	11/LO/1455	A Long Term Followup Registry Study of Subjects Who Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection	8	01/09/2018	Open	N/A
70245	15/NW/0405	A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with Mild to Moderate Alzheimer's Disease (LUPIN)	3	01/08/2016	Open	N/A
70246	15/LO/0743	A phase 1, randomised, double-blind, placebo-controlled, multi-centre, ascending-dose trial to evaluate the safety, tolerability and immunogenicity of Vaccine FP-02.2 in HBeAg-negative hepatitis B patients as an add-on treatment to entecavir or tenofovir.	8	31/01/2016	Open	N/A
70247	15/LO/1163	A phase 3b, randomized, double-blind switch study to evaluate F/TAF in HIV-1 infected subjects who are virologically suppressed on regimens containing ABC/3TC.	6	29/02/2016	Open	N/A
70248	14/LO/2014	A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)	4	31/12/2016	Open	N/A
70249	15/LO/1087	An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand Disease	3	28/02/2018	Open	N/A
70250	15/LO/1138	A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials.	3	31/07/2016	Open	N/A
70253	15/LO/0519	AI438-047: Attachment inhibitor study in HTE patients with MDR HIV-1	2	31/12/2016	Open	N/A
70254	14/SS/1087	A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease.	3	02/02/2017	Open	N/A
70255	15/LO/0984	Phase III randomised clinical trial of Lurbinectedin (PM01183) versus pegylated liposomal Doxorubicin or Topotecan in patients with platinum-resistant ovarian cancer (CORAIL Trial)	4	01/03/2019	Open	N/A
70257	15/LO/1289	An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.	20	31/05/2017	Open	N/A
70258	15/LO/1074	A multicentre, randomised, placebo controlled, double blinded, multiple dose trial investigating safety, pharmacokinetics and pharmacodynamics of concizumab administered subcutaneously to haemophilia A subjects.	1	31/03/2017	Open	N/A
70260	15/EM/0230	A Three Arm Double blind, Randomised Multicentre Study to Investigate the NonInferiority of a Soft Gel Capsule of Ibuprofen Lipid Formulation (total daily dose 1200 mg) versus a Standard Soft Gel Ibuprofen Capsule (total daily dose 1200 mg and 2400 mg) in the Treatment of Patients with Episodic Knee Arthralgia/Flaring Knee Pain.	10	31/12/2017	Open	N/A
70261	15/NW/0700	A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection.	2	31/03/2016	Open	N/A
70262	15/NW/0481	A prospective, randomized, double-blind, multicenter, phase 3 study to assess the safety and efficacy of intravenous ceftolozane/tazobactam compared with meropenem in adult patients with ventilated nosocomial pneumonia.	5	31/12/2017	Open	N/A
70459	15/WS/0153	A phase 3, randomized, double-blind, placebo-controlled study evaluation the efficacy and safety of a human monoclonal antibody, REGN2222, for the prevention of medically attended RSV infection in pre-term infants.	2	31/01/2016	Open	N/A
70239	14/YH/1260	Clinical Investigation Plan (CIP) for Safety and Performance Study of Large Hole Vascular Closure Device – FRONTIER II study	10	06/06/2016	Suspended	N/A
70256	14/SC/1340	LEGATO-HD-Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5,1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease.	5	31/07/2016	Suspended	N/A
70176	13/LO/0261	H7T-MC-TADO: A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease.	1	31/05/2014	Withdrawn	N/A
70177	12/WA/0250	Efficacy, Pharmaokinetcs and Safety of BI 695500 versus Rituximab in Patients with Moderately to Severe Active Rheumatoid Arthritis: A Randomised, Double-Blind, Parallel arm, Multiple dose, Activator Comparator Trial.	1	17/03/2015	Withdrawn	N/A
70238	15/LO/0018	A randomized, doubleblind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysm.	10	31/12/2016	Withdrawn	N/A
70252	15/LO/0652	AI468-038 . A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults.	5	31/12/2015	Withdrawn	N/A